Beacon Pharmaceuticals PLC (DSE:BEACONPHAR)
Bangladesh
· Delayed Price · Currency is BDT 104.00
+3.80 (3.79%)
At close: Apr 28, 2026
Beacon Pharmaceuticals Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2016 |
| Revenue | 14,785 | 12,543 | 10,702 | 8,510 | 8,023 | 7,121 | Upgrade
|
| Revenue Growth (YoY) | 27.69% | 17.20% | 25.75% | 6.07% | 12.66% | 27.37% | Upgrade
|
| Cost of Revenue | 7,212 | 6,072 | 5,215 | 4,251 | 3,906 | 3,452 | Upgrade
|
| Gross Profit | 7,573 | 6,471 | 5,487 | 4,259 | 4,116 | 3,669 | Upgrade
|
| Selling, General & Admin | 4,849 | 4,137 | 3,672 | 3,295 | 2,499 | 2,307 | Upgrade
|
| Other Operating Expenses | - | - | - | -14.86 | - | - | Upgrade
|
| Operating Expenses | 4,849 | 4,137 | 3,672 | 3,280 | 2,499 | 2,307 | Upgrade
|
| Operating Income | 2,724 | 2,334 | 1,814 | 979.12 | 1,617 | 1,362 | Upgrade
|
| Interest Expense | -1,327 | -1,308 | -1,003 | -460.92 | -337.96 | -164.82 | Upgrade
|
| Interest & Investment Income | 330.78 | 330.78 | 227.86 | 155.13 | 0.32 | 3.24 | Upgrade
|
| Currency Exchange Gain (Loss) | -73.24 | -73.24 | -93.69 | 2.68 | 0.5 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 57.32 | 17.79 | 13.85 | - | 9.81 | -1.98 | Upgrade
|
| EBT Excluding Unusual Items | 1,712 | 1,301 | 959.82 | 676.01 | 1,290 | 1,198 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.01 | -0.01 | -6.5 | 3.07 | 3.04 | - | Upgrade
|
| Pretax Income | 1,712 | 1,301 | 953.32 | 679.07 | 1,293 | 1,198 | Upgrade
|
| Income Tax Expense | 474.12 | 354.53 | 432.31 | 169.23 | 357.93 | 334.99 | Upgrade
|
| Net Income | 1,238 | 946.51 | 521.01 | 509.84 | 935.04 | 863.17 | Upgrade
|
| Net Income to Common | 1,238 | 946.51 | 521.01 | 509.84 | 935.04 | 863.17 | Upgrade
|
| Net Income Growth | 117.11% | 81.67% | 2.19% | -45.47% | 8.33% | 126.74% | Upgrade
|
| Shares Outstanding (Basic) | 231 | 231 | 231 | 231 | 231 | 231 | Upgrade
|
| Shares Outstanding (Diluted) | 231 | 231 | 231 | 231 | 231 | 231 | Upgrade
|
| EPS (Basic) | 5.36 | 4.10 | 2.26 | 2.21 | 4.05 | 3.74 | Upgrade
|
| EPS (Diluted) | 5.36 | 4.10 | 2.26 | 2.21 | 4.05 | 3.74 | Upgrade
|
| EPS Growth | 117.11% | 81.67% | 2.19% | -45.47% | 8.33% | 126.74% | Upgrade
|
| Free Cash Flow | 726.84 | 778.5 | -1,275 | -1,193 | -637.07 | -116.85 | Upgrade
|
| Free Cash Flow Per Share | 3.15 | 3.37 | -5.52 | -5.17 | -2.76 | -0.51 | Upgrade
|
| Dividend Per Share | 2.100 | 2.100 | 2.000 | 1.600 | 1.600 | 1.500 | Upgrade
|
| Dividend Growth | 5.00% | 5.00% | 25.00% | - | 6.67% | - | Upgrade
|
| Gross Margin | 51.22% | 51.59% | 51.27% | 50.05% | 51.31% | 51.52% | Upgrade
|
| Operating Margin | 18.42% | 18.61% | 16.96% | 11.51% | 20.16% | 19.12% | Upgrade
|
| Profit Margin | 8.37% | 7.55% | 4.87% | 5.99% | 11.65% | 12.12% | Upgrade
|
| Free Cash Flow Margin | 4.92% | 6.21% | -11.91% | -14.02% | -7.94% | -1.64% | Upgrade
|
| EBITDA | 3,407 | 2,966 | 2,342 | 1,498 | 2,057 | 1,747 | Upgrade
|
| EBITDA Margin | 23.04% | 23.64% | 21.89% | 17.60% | 25.64% | 24.53% | Upgrade
|
| D&A For EBITDA | 683.21 | 631.4 | 527.78 | 518.92 | 439.7 | 385.16 | Upgrade
|
| EBIT | 2,724 | 2,334 | 1,814 | 979.12 | 1,617 | 1,362 | Upgrade
|
| EBIT Margin | 18.42% | 18.61% | 16.96% | 11.51% | 20.16% | 19.12% | Upgrade
|
| Effective Tax Rate | 27.70% | 27.25% | 45.35% | 24.92% | 27.68% | 27.96% | Upgrade
|
| Advertising Expenses | - | 83.97 | 72.55 | 69.04 | 68.5 | 52.97 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.